Merck (MRK) announced it has initiated three Phase 2b trials evaluating the safety and efficacy of tulisokibart, an investigational humanized monoclonal antibody targeting tumor necrosis factor-like cytokine 1A, in patients with three immune-mediated inflammatory diseases: MK-7240-12 (NCT06956235) studying patients with moderate to severe hidradenitis suppurativa; MK-7240-013 (NCT07133633) studying patients with radiographic axial spondyloarthritis (r-axSpA; also known as ankylosing spondylitis); MK-7240-014 (NCT07176390) studying patients with rheumatoid arthritis. Global recruitment of these trials has begun, targeting enrollment of more than 640 patients across the three studies.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK:
- Sector Spotlight: UnitedHealth shareholder proposes split of CEO, chair role
- Trump Weekly: White House announces drug pricing deal with Pfizer
- Closing Bell Movers: Bentley Systems up 5% on S&P MidCap 400 entry
- Trump Trade: White House announces drug pricing deal with Pfizer
- Trump outlines plan for next round of Medicare drug price talks, Bloomberg says